Cargando…
Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection
Herein, we demonstrated the development and characterization of a dry powder inhaler (DPI) formulation of edoxaban (EDX); and investigated the in-vitro anticoagulation effect for the management of pulmonary or cerebral coagulopathy associated with COVID-19 infection. The formulations were prepared b...
Autores principales: | Rashid, Md Abdur, Muneer, Saiqa, Mendhi, Jayanti, Sabuj, Mohammad Zaidur Rahman, Alhamhoom, Yahya, Xiao, Yin, Wang, Tony, Izake, Emad L., Islam, Nazrul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463814/ https://www.ncbi.nlm.nih.gov/pubmed/34560207 http://dx.doi.org/10.1016/j.ijpharm.2021.121122 |
Ejemplares similares
-
Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
por: Rashid, Md Abdur, et al.
Publicado: (2021) -
Impact of Leucine and Magnesium Stearate on the Physicochemical Properties and Aerosolization Behavior of Wet Milled Inhalable Ibuprofen Microparticles for Developing Dry Powder Inhaler Formulation
por: Sharif, Shahjabeen, et al.
Publicado: (2023) -
Stability of Inhaled Ciprofloxacin-Loaded Poly(2-ethyl-2-oxazoline) Nanoparticle Dry Powder Inhaler Formulation in High Stressed Conditions
por: Sabuj, Mohammad Zaidur Rahman, et al.
Publicado: (2022) -
Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban
por: Rashid, Md Abdur, et al.
Publicado: (2022) -
Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
por: Rashid, Md Abdur, et al.
Publicado: (2019)